sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Neuropathic Pain Market Size Study, by Drug Class, by Indication, by Distribution Channel and Regional Forecasts 2022-2032

Global Neuropathic Pain Market Size Study, by Drug Class, by...

Home / Categories / Healthcare
Global Neuropathic Pain Market Size Study, by Drug Class, by Indication, by Distribution Channel and Regional Forecasts 2022-2032
Global Neuropathic Pain Market Size...
Report Code
RO1/103/2874

Publish Date
22/Aug/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
The Global Neuropathic Pain Market is valued approximately at USD 8.14 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.73% over the forecast period 2024-2032. Neuropathic pain, caused by damage or disease affecting the somatosensory nervous system, is often linked to abnormal sensations such as dysesthesia, or continuous and paroxysmal components. Common symptoms include burning or coldness, pins and needles, numbness, and itching. Medications like opioids, capsaicin, anticonvulsants, and antidepressants are commonly used for neuropathic pain management. Furthermore, the aging population, which is more prone to conditions such as diabetes and shingles leading to neuropathic pain, drives the market. The growing global burden of chronic diseases associated with nerve damage, such as HIV, postherpetic neuralgia, trigeminal neuralgia, and fibromyalgia, also contributes to market expansion. For instance, according to UNAIDS, 39 million people were living with HIV in 2022, with a significant portion experiencing neuropathic pain due to peripheral neuropathy.

The market is driven by the increasing demand for drugs for neuropathic pain, growing awareness initiatives by various government associations, and a rise in clinical trials for neuropathic pain treatments. For instance, in May 2023, Algiax Pharmaceuticals announced the continuation of its Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain, following a positive mid-enrollment interim analysis. Moreover, the rise in the prevalence of conditions causing neuropathic pain, such as spinal stenosis and diabetic neuropathy, is a key factor driving market growth. Additionally, chemotherapy-induced peripheral neuropathy, a common side effect of cancer treatments, further propels the demand for neuropathic pain medications. According to the American Cancer Society, numerous new cancer cases were diagnosed in the U.S. in 2021, emphasizing the need for effective pain management solutions. However, challenges such as high cost of drug development and stringent regulatory approvals restrain demand for the Global Neuropathic Pain Market during the forecast period 2024-2032.

The key regions considered for the Global Neuropathic Pain Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. In 2023, North America was the dominating regional market in terms of revenue. The region boasts advanced healthcare infrastructure and high healthcare expenditure, which facilitates extensive research and development in pain management therapies. The prevalence of chronic diseases, such as diabetes and cancer, which often lead to neuropathic pain, is relatively high in North America, driving demand for effective treatments. Furthermore, the presence of major pharmaceutical companies and research institutions accelerates the development and commercialization of innovative neuropathic pain medications and therapies. Regulatory bodies like the FDA provide a structured pathway for drug approvals, ensuring a steady pipeline of new treatments. Additionally, growing awareness about neuropathic pain among healthcare professionals and patients, along with strong support from healthcare insurance systems, further boosts the market. Furthermore, the Asia-Pacific region is expected to grow at the fastest rate over the forecast period 2024-2032.

Major market players included in this report are:
Abbott Laboratories
Collegium Pharmaceutical, Inc.
Eli Lilly and Company
Glenmark Pharmaceuticals Limited
Grunenthal
Mallinckrodt Pharmaceuticals
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd
The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Antidepressants
Tricyclic Antidepressants
Serotonin-Noradrenaline Reuptake Inhibitors (SNRI)
Anticonvulsant
Opioids
Capsaicin
Others
By Indication:
Diabetic Neuropathy
Spinal Stenosis
Chemotherapy-Induced Peripheral Neuropathy
Others
By Distribution Channel:
Hospital Pharmacies
Drugs Stores and Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
Australia
India
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com